Innoviva vs Liquidia
INVA and LQDA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How INVA and LQDA compare
Liquidia is the larger company, worth 3.8 times as much as Innoviva ($5.1B against $1.3B).
On earnings, Innoviva is cheaper: it trades at 9.3× trailing earnings, against 40.8× for Liquidia.
Liquidia grew revenue faster over the last twelve months (2234% versus 12.8% for Innoviva).
Innoviva scores higher on the StockData Score (14 against 8 for Liquidia), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | INVA | LQDA |
|---|---|---|
| Size and price | ||
| Market cap | $1.3B | $5.1B |
| Share price | $18.30 | $56.73 |
| Change, 1 year | −17.8% | 102% |
| Change, 5 years | 8.2% | 1280% |
| Beta (5Y) | 0.20 | 1.00 |
| Employees | 159 | 216 |
| StockData Score | ||
| Total score | 14 (better) | 8 |
| Valuation score | 5 (better) | 0 |
| Growth score | 2 | 2 |
| Performance score | 1 | 3 (better) |
| Health score | 6 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 9.3× (better) | 40.8× |
| P/S | 3.0× (better) | 11.3× |
| P/B | 1.2× (better) | 26.0× |
| EV/EBITDA | 5.9× (better) | 28.2× |
| P/FCF | 7.2× (better) | 33.7× |
| PEG | 0.80 | – |
| FCF yield | 13.8% (better) | 3.0% |
| Fair value | $30.22 | $32.46 |
| Margin of safety | 39.5% (better) | −74.8% |
| Growth | ||
| Revenue growth (TTM) | 12.8% | 2234% (better) |
| Revenue growth, 5Y average | 4.1% | 192% (better) |
| EPS growth, 5Y average | 10.3% | – |
| Profitability | ||
| Gross margin | 74.5% | – |
| Operating margin | 38.8% (better) | 37.4% |
| Net margin | – | 30.7% |
| FCF margin | 41.6% (better) | 33.4% |
| Return on equity | – | 132% |
| Return on invested capital | 18.0% | – |
| Financial health | ||
| Debt / equity | 0.23 | – |
| Net debt / EBITDA | −1.90 | – |
| Interest coverage | 8.6× (better) | 6.3× |
| Current ratio | 15.44 (better) | 2.31 |
| Altman Z-score | 3.47 | 10.49 (better) |
| Piotroski F-score | – | 4 |
| Dividends and buybacks | ||
| Buyback yield | 5.9% | – |
| Shareholder yield | 5.9% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 104% | 81.1% |
| Held by insiders | 5.4% | 19.5% |
| Insider net buying, 12 months | – | −$227M |
| Short interest, % of float | 11.0% | 24.3% |
Go deeper
- INVA stock overview
- INVA income statement
- INVA valuation and score
- LQDA stock overview
- LQDA income statement
- LQDA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.